Table of Contents

company-logo

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. The company was founded in 2005 and is based in Pasadena, California.

Lixte Biotechnology Dividend Announcement

• Lixte Biotechnology does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Lixte Biotechnology dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Lixte Biotechnology Dividend History

Lixte Biotechnology Dividend Yield

Lixte Biotechnology current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Lixte Biotechnology stock? Use our calculator to estimate your expected dividend yield:

Lixte Biotechnology Financial Ratios

P/E ratio-0.92
PEG ratio0.09
P/B ratio1.65
ROE-112.90%
Payout ratio0.00%
Current ratio6.33
Quick ratio6.33
Cash Ratio6.16

Lixte Biotechnology Dividend FAQ

Does Lixte Biotechnology stock pay dividends?
Lixte Biotechnology does not currently pay dividends to its shareholders.
Has Lixte Biotechnology ever paid a dividend?
No, Lixte Biotechnology has no a history of paying dividends to its shareholders. Lixte Biotechnology is not known for its dividend payments.
Why doesn't Lixte Biotechnology pay dividends?
There are several potential reasons why Lixte Biotechnology would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Lixte Biotechnology ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Lixte Biotechnology has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Lixte Biotechnology a dividend aristocrat?
Lixte Biotechnology is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Lixte Biotechnology a dividend king?
Lixte Biotechnology is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Lixte Biotechnology a dividend stock?
No, Lixte Biotechnology is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Lixte Biotechnology stocks?
To buy Lixte Biotechnology you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Lixte Biotechnology stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.